Soleno Therapeutics Achieves Profitability, Reports Strong VYKAT XR Launch & $190M FY25 Revenue

summarizeSummary

Soleno Therapeutics announced a highly successful first year of VYKAT XR commercialization, achieving full-year 2025 profitability with $20.9 million in net income and $190.4 million in product revenue, alongside a strong cash position and a $100 million share repurchase program.

check_boxKey Events

• Achieved Full-Year Profitability

  Reported net income of $20.9 million for the full year 2025, a significant turnaround from a substantial loss in 2024.

• Strong VYKAT XR Launch Revenue

  Generated $190.4 million in net product revenue from VYKAT XR sales in its first nine months post-approval.

• Robust Commercial Metrics

  Recorded 1,250 patient start forms and 859 active patients on VYKAT XR by year-end 2025, indicating strong market penetration.

• Solid Financial Position

  Ended 2025 with $506.1 million in cash, cash equivalents, and marketable securities, supported by $48.7 million in Q4 operating cash flow.

auto_awesomeAnalysis

This 8-K signals a significant positive inflection point for Soleno Therapeutics, transitioning from a development-stage company to a profitable commercial entity. The successful launch of VYKAT XR, generating $190.4 million in revenue in its first nine months, demonstrates strong market adoption and execution. Achieving full-year profitability and generating substantial operating cash flow significantly de-risks the company's financial profile. The $100 million accelerated share repurchase program further underscores management's confidence in the company's financial health and future prospects. Investors should view these results as a strong validation of the company's strategy and commercial capabilities, potentially leading to a re-evaluation of its long-term growth trajectory.